Synthetic studies on selective type 4 phosphodiesterase (PDE 4) inhibitors. 1. Structure-activity relationships and pharmacological evaluation of 1,8-naphthyridin-2(1H)-one derivatives

Chemical and Pharmaceutical Bulletin

Volumn 50, Issue 8, 2002, Pages 1050-1059

  Takayama, Kazuhisa ^a   Iwata, Masahiro ^a   Hisamichi, Hiroyuki ^a   Okamoto, Yoshinori ^a   Aoki, Motonori ^a   Niwa, Akira ^b  

^a ASTELLAS PHARMA INC   (Japan)

^b INSTITUTE FOR DEVELOPMENTAL RESEARCH   (Japan)

Author keywords

1,8 naphthyridin 2(1H) one; Phosphodiesterase 4 inhibitor; Rolipram; YM 10335

Indexed keywords

PHOSPHODIESTERASE I; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHODIESTERASE V; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; YM 10335; 3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CARRAGEENAN; NAPHTHYRIDINE DERIVATIVE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; NONHUMAN; PLEURISY; RAT; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; ANIMAL; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DRUG ANTAGONISM; DRUG SCREENING; ENZYMOLOGY; METABOLISM; METHODOLOGY;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; CARRAGEENAN; DRUG EVALUATION, PRECLINICAL; HUMANS; MALE; NAPHTHYRIDINES; PHOSPHODIESTERASE INHIBITORS; PLEURISY; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0036691317     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.50.1050     Document Type: Article

References (18)

1. Kaliner M., Austen K. F., Biochem. Pharmacol., 23, 763-771 (1974).
2. Beavo J. A., Reifsnyder D. H., Trends Pharmacol. Sci., 11, 150-155 (1990).
3. Beavo J. A., Physiol. Rev., 75, 725-748 (1995).
4. Conti M., Jin S.-L. C., Prog. Nucleic Acid Res. Mol. Biol., 63, 1-38 (1999).
5. Dent G., Giembycz M. A., Evans P. M., Rabe K. F., Baenes P. J., J. Pharmacol. Exp. Ther., 271, 1167-1174 (1994).
6. Griswold D. E., Webb E. F., Breton J., White J. R., Marshall P. J., Torphy T. J., Inflammation, 17, 333-344 (1993).
7. Underwood D. C., Osborn R. R., Novak L. B., Matthews J. K., Newsholme S. J., Undem B. J., Hand J. M., Torphy T. J., J. Pharmacol. Exp. Ther., 266, 306-313 (1993).
8. Turner C. R., Andresen C. J., Smith W. B., Watson J. W., Am. J. Respir. Crit. Care Med., 149, 1153-1159 (1994).
9. Trophy T. J., Undem B. J., Thorax, 46, 512-523 (1991).
10. Nicholson C. D., Shahid M., Pulm. Pharmacol., 7, 1-17 (1994).
11. Giembycz M. A., Dent G., Clin. Exp. Allergy, 22, 337-344 (1992).
12. Palfreyman M. N., Drugs of the Future, 20, 793-804 (1995).
13. Kubo K., Ito N., Isomura Y., Sozu I., Homma H., Murakami M., Yakugaku Zasshi, 99, 788-793 (1979).
14. Turner J. A., J. Org. Chem., 55, 4744-4750 (1990).
15. Crespo M. I., Pages L., Vega A., Seggrra V., Lopez M., Domenech T., Miralpeix M., Beleta J., Ryder H., Palacios M., J. Med. Chem., 41, 4021-4035 (1998).
16. Schmiechen R., Horowski R., Palenschat D., Paschelke G., Wachtel H., Kehr W., Ger. Offen. 2413935 [Chem. Abstr., 84, 30878u (1976)].
17. Warrellow G. H., Boyd E. C., Alexander R. P., PCT Int. Appl. WO9414742A1 [Chem. Abstr., 122, 265044m (1995)].
18. Grau M., Guasch J., Montero J. L., Felipe A., Carrasco E., Julia S., Arzneimittel-Forschung, 41, 1265-1276 (1991).